Abstract Details

Title Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: a case-controlled magnetization transfer ratio study

Topic Multiple Sclerosis

Presentation(s) P5 - Poster Session 5 (5:30 PM-6:30 PM)

Poster/Presentation
Number 15-045

Objective To evaluate associations between Epstein-Barr virus (EBV)-specific humoral response and magnetization transfer ratio (MTR)-derived measure in multiple sclerosis (MS) patients and healthy controls (HCs).

Background EBV infection has been associated with higher clinical activity and risk of multiple sclerosis MS. However, studies regarding the anti-EBV humoral response and its effect on non-conventional MRI imaging are currently lacking.

Design/Methods The study included 101 MS patients (69 relapsing-remitting MS (RRMS) and 32 secondary-progressive MS (SPMS)) and 41 HCs who underwent clinical, serological, and MRI investigations. MTR values of T1-, T2-lesion volume (LV), normal-appearing (NA) brain tissue (NABT), gray matter (NAGM) and white matter (NAWM) were obtained. Enzyme-linked immunosorbent assay was used to quantify anti-Epstein Barr nuclear antigen (EBNA) antibody levels. Partial correlations corrected for MRI strength were used and Benjamini-Hochberg-adjusted p-values <0.05 were considered significant.

Results MS patients had significantly higher anti-EBNA titer when compared to HCs (median 107.9 U/ml vs. 27.8 U/ml, p<0.001). Although numerically higher in the RRMS group, there were no significant anti-EBNA titer differences between the RRMS and SPMS subgroups (median 132.6 U/ml vs. 80.4 U/ml). Within the MS group, higher serum anti-EBNA titer was significantly correlated with lower T1-LV MTR (r=-0.287, p=0.035). Within the RRMS group, higher serum anti-EBNA titer was associated with T1-LV MTR (r=-0.524, p<0.001) and NAGM MTR (r=-0.308, p=0.043). These associations were not present in HCs nor in SPMS patients.

Conclusions Greater EBV humoral response measured as anti-EBNA antibodies is associated with lower GM MTR changes and focal destructive lesion pathology in RRMS patients.

Authors/Disclosures
Michael G. Dwyer III, MD, PhD (Buffalo Neurological Analysis Center) PRESENTER	Dr. Dwyer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Dwyer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Keystone Heart, Ltd. Dr. Dwyer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. The institution of Dr. Dwyer has received research support from Novartis. The institution of Dr. Dwyer has received research support from Keystone Heart, Ltd. The institution of Dr. Dwyer has received research support from Bristol Myers Squibb. The institution of Dr. Dwyer has received research support from Roche.
Dejan Jakimovski, MD, PhD (Buffalo Neuroimaging Analysis Center, University at Buffalo)	Dr. Jakimovski has nothing to disclose.
Murali Ramanathan, PhD (University At Buffalo)	The institution of Dr. Ramanathan has received research support from DoD. Dr. Ramanathan has received publishing royalties from a publication relating to health care.
Bianca Weinstock-Guttman, MD (Department of Neurology, University At Buffalo)	Dr. Weinstock-Guttman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis . Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme &Sanofi. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen . Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Weinstock-Guttman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. Dr. Weinstock-Guttman has received personal compensation in the range of $0-$499 for serving as a Reviewer with NIH.
Niels Bergsland (Buffalo Neuroimaging Analysis Center / State University of New York At Buffalo)	Prof. Bergsland has nothing to disclose.
	No disclosure on file
Ellen Carl, MS (The Jacobs Neurological Institute)	No disclosure on file
Robert Zivadinov, MD, PhD, FAAN (Buffalo Neuroimaging Analysis Center)	The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Omnicuris. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Myrobalan. Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Zivadinov has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bristol Myers Squibb. The institution of Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen.

��ɫ��

��ɫ��